bristol-myers squibb stock news

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

bovnews · 10h

Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at $52.

MarketWatch on MSN · 6d

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics